Rifalazil

Overview

Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase. Rifalazil (KRM-1648; ABI-1648) is an antibiotic , exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori , C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml. Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection , Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB).

Application

Products | Products > Disease Areas > Mycobacterium Tuberculosis Infection | Products > Disease Areas > Clostridium Difficile Infection | Products > Disease Areas > Chlamydia Infection | Products > Disease Areas > Infection | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Bacterial Infection | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Infection | Products > Signaling Pathways > Antibiotic | Products > Signaling Pathways > DNA/RNA Synthesis | Products > Signaling Pathways > Bacterial

Product Information

• Catalog No.: HY-105099
• CAS No.: 129791-92-0
• Molecular Formula: C51H64N4O13
• Molecular Weight: 941.07
• Purity: 99.64%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 2.2 mg/mL (2.34 mM); Clear solution
• Availability: In-stock

Source

Original product source